![]() ![]() With the transformation of hospitals toward smart treatment centers, digitalization is entering the health sector and supporting hospital employees through intuitive digital data management and robotics. A first automation concept will be shown, including a system architecture based on current Industry 4.0 approaches for AI integration. In this perspective, we will be discussing current challenges and opportunities of the patient-specific but highly automated, AI-enabled CAR-T cell manufacturing. The smart integration of automated CAR-T cell manufacturing platforms into hospitals enables the independent manufacture of autologous CAR-T cell products. Using Artificial Intelligence (AI) to interpret the data collected on the platform will provide valuable process insights and drive decisions for process optimization. ![]() Automation will increase the cost-effectiveness and robustness of manufacturing. An automated AI-driven CAR-T cell manufacturing platform in smart manufacturing hospitals (SMH) is being developed to address these challenges. However, these devices are not equipped with the process analytical technology necessary to fully characterize and control the process. Semi-automated devices such as the Miltenyi Prodigy ® were developed to reduce hands-on production time. ![]() New manufacturing approaches are needed to lower costs to improve manufacturing capacity and shorten provision times. This leads to high manufacturing costs and limited clinical success, preventing the widespread use of CAR-T cell therapies. However, the chance of clinical success remains relatively low as the applicability of CAR-T cell therapy suffers from long, labor-intensive manufacturing and a lack of comprehensive insight into the bioprocess. CAR-T cell therapies take a pioneering role in autologous gene therapy with three EMA-approved products. 7Laboratory for Machine Tools and Production Engineering (WZL) of RWTH Aachen University, Aachen, GermanyĬAR-T cell therapy is a promising treatment for acute leukemia and lymphoma.5Lehrstuhl für Zelluläre Immuntherapie, Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.4Prometheus the Leuven R&D Translational Division of Skeletal Tissue Engineering, KU Leuven, Leuven, Belgium.3Skeletal Biology and Engineering Research Centre, Department of Development and Regeneration, KU Leuven, Leuven, Belgium.2Institute of Chemical Engineering Sciences, Foundation for Research and Technology-Greece (FORTH), Patras, Greece.1Fraunhofer Institute for Production Technology IPT, Aachen, Germany.Simon Hort 1 *, Laura Herbst 1, Niklas Bäckel 1, Frederik Erkens 1, Bastian Niessing 1, Maik Frye 1, Niels König 1, Ioannis Papantoniou 2,3,4, Michael Hudecek 5, John J. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |